Navigation Links
Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
Date:11/14/2011

ROCKVILLE, Md., Nov. 14, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that the ongoing Phase I trial to test its spinal cord stem cells in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) was featured Wednesday night on Fox 5 News in Atlanta  http://www.neuralstem.com/neuralstem-in-the-news

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

The trial was recently approved by the FDA to advance to cervical injections.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company has com
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Neuralstem Reports Second Quarter Financial Results and Highlights
2. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
3. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
4. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
6. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
7. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
8. Neuralstem Completes $5.25 Million Financing
9. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
10. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
11. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Deep Knowledge Ventures last week sponsored ... Longevity Research’ and welcomed a host of London-based ... Innovation Center for the event, organised by the ... The meeting highlighted the need for both philanthropic ... disease, as well as the crucial role of ...
(Date:7/10/2014)... Terascala, the industry leader in HPC management ... vice president of product management for Flexera Software, has ... Terascala’s software when combined with leading compute and storage ... and most reliable solutions for processing big data. , ... and broaden its product portfolio. His leadership in startups ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... Annualized Relapse Rate and was Well Tolerated in MS Patients -- PARIS, August 30, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc. (OTC Bulletin Board: GOVX ), a biotechnology ... announced the results of its Annual Shareholders Meeting, held on ... seven nominees for directors of the company to serve until ... are duly elected or appointed and qualified. They are: ...
... Bioheart, Inc., (OTC Bulletin Board: BHRT ) ... with stem cell therapy on the first two congestive ... Angeles Tijuana through its Center of Excellence, Regenerative Medicine ... an agreement to establish a Center of Excellence for ...
Cached Biology Technology:Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 2Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 3Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 4Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 5Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 6Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 7Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 8Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 9GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 2GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 3GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 4Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 2Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 3Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 4
(Date:7/11/2014)... team of researchers, including scientists from the Max Planck ... reported a major step in understanding photosynthesis, the process ... the oxygen in its atmosphere and which is therefore ... , The researchers report the first direct visualization ... the step in which a specific protein complex, photosystem ...
(Date:7/11/2014)... stem cells can stimulate neurogenesis in the brain of ... and improve tissue and function injury under the condition ... therapeutic effect of adipose-derived stem cells (ADSCs) transplantation in ... injury and neurogenesis in the brain of AD mice. ... Sciences, Tsinghua University, China transplanted ADSCs into the hippocampus ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... the "International Biometrics Technology Market - Industry Analysis ... report to their offering. ... attacks and crimes has created a need for high ... methods used for personnel authentication such as username and ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... ARBORA common test used to determine mercury exposure from ... the toxic metal released from fillings, according to University ... fillings slowly release mercury vapor into the mouth. But ... of whether this exposure presents a significant health risk ...
... process that releases the energy in coal without burning ... passed a milestone on the route to possible commercial use, ... Energy & Fuels describes results of a successful 200-hour ... two inexpensive but highly polluting forms of coal. ...
... 2013) - House paint containing dangerous,concentrations of lead is ... and the,company is refusing to remove the paint from ... regulations to restrict the lead content of paint in,Cameroon ... of,Occupational Knowledge International (OK International) and co-author of a ...
Cached Biology News:Measuring mercury: Common test may overestimate exposure from dental amalgam fillings 2Measuring mercury: Common test may overestimate exposure from dental amalgam fillings 3US company identified as manufacture of lead paint in Africa 2